Stockreport

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Silence Therapeutics Plc - American Depository Share  (SLN) 
PDF Silence also announced positive topline 36-week data from ongoing phase 2 study of zerlasiran in patients with high lipoprotein(a)Company to host conference call and web [Read more]